Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Israel’s Taro Cancels Acquisition Pact With India’s Sun Pharma

This article was originally published in PharmAsia News

Executive Summary

Israel's Taro Pharmaceuticals has canceled its year-old agreement with India's Sun Pharmaceutical Industries to agree to a Sun subsidiary's takeover of the firm. Sun and Taro agreed last year to a $455 million acquisition by Aditya Acquisition, a Sun subsidiary, but Taro directors have voted unanimously to cancel the agreement after Taro managed to turn around its fortunes in the ensuing months. Sun, which owns just over a third of Taro, had offered to raise the original share offer, but Taro directors turned it down and exercised an agreement provision that allowed the Israeli drug maker to cancel the merger

You may also be interested in...

India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales

NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts